{"id":949703,"date":"2026-04-07T23:38:27","date_gmt":"2026-04-08T03:38:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/"},"modified":"2026-04-07T23:38:27","modified_gmt":"2026-04-08T03:38:27","slug":"mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/","title":{"rendered":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy"},"content":{"rendered":"
\n

\n Partnering with Parent Project Muscular Dystrophy to ensure timely access to <\/em>
\n the trial for eligible patients<\/em>\n <\/p>\n

\n ~15,000 children are living with DMD in the U.S.<\/em>\n <\/p>\n

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil\u00ae<\/sup> (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1<\/sup><\/p>\n

Ryoncil\u00ae<\/sup> is the first mesenchymal stromal cell (MSC) product approved<\/a> by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)2<\/sup>. This new registrational trial builds on Ryoncil\u2019s\u00ae<\/sup> proven safety in children, evidence of efficacy in DMD preclinical models, and FDA-approved manufacturing process. Leveraging Ryoncil’s\u00ae<\/sup> anti-inflammatory mechanism of action in SR-aGvHD, Mesoblast aims to reduce the inflammatory cascade characteristic of DMD, preserve muscle function, and slow disease progression.<\/p>\n

The trial will randomize 76 patients aged 5 to 9 years to either Ryoncil\u00ae<\/sup> (7 infusions of 2 x 106<\/sup> cells\/kg over 9 months) or placebo, on top of standard of care. The trial\u2019s primary endpoint will be time-to-stand at nine months, a validated FDA endpoint for approval. To support the successful execution of this study, Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to foster patient identification and trial awareness through proactive community engagement.<\/p>\n

\u201cThis study represents an important step forward in potentially addressing the inflammatory component of DMD, a major driver of disease progression,\u201d said Aravindhan Veerapandiyan, MD, Director of the Comprehensive Neuromuscular Program at Arkansas Children\u2019s Hospital, and Principal Investigator of the study. \u201cBy leveraging the anti-inflammatory effects of Ryoncil, we aim to intervene at a stage where muscle tissue may still be preserved, potentially altering the trajectory of the disease.\u201d<\/p>\n

\u201cWe are very pleased to have received clearance to proceed directly to a registrational study for DMD based on our preclinical data in DMD animal models and our extensive safety data in children with SR-aGvHD. Our experience with Ryoncil suggests that we may have a unique approach to help with this devastating disease in children,\u201d said Silviu Itescu, Chief Executive of Mesoblast<\/p>\n

\n About Duchenne Muscular Dystrophy (DMD)<\/strong>
\n
Duchenne Muscular Dystrophy (DMD) is a X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the muscle leads to loss of ambulation, respiratory failure and cardiomyopathy ultimately leading to death by the third decade.<\/p>\n

While gene therapies that replace or increase the missing dystrophin protein are groundbreaking, they are not a complete cure. Chronic inflammation of skeletal and heart muscle remains a major underlying cause of progressive weakness, leading to loss of ambulation, reliance on wheelchair assistance and death in DMD. Corticosteroid use has improved survival but its effects plateau and long-term usage have serious side effects.<\/p>\n

\n About Parent Project Muscular Dystrophy<\/strong>
\n
Parent Project Muscular Dystrophy (PPMD), a leading patient advocacy organization, to support patient identification, education, and trial awareness. The organization was founded in 1994: https:\/\/www.parentprojectmd.org\/<\/a>.<\/p>\n

\n About Mesoblast <\/strong>
\n
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company\u2019s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.<\/p>\n

Mesoblast\u2019s Ryoncil\u00ae<\/sup> (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com<\/a>.<\/p>\n

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil\u00ae<\/sup> is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.<\/p>\n

\n About Mesoblast intellectual property: <\/strong>Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.<\/p>\n

\n About Mesoblast manufacturing: <\/strong>The Company\u2019s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.<\/p>\n

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com<\/a>, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast<\/p>\n

\n References \/ Footnotes<\/strong>\n <\/p>\n

    \n
  1. \n https:\/\/cureduchenne.org\/about\/what-is-duchenne\/#:~:text=Prevalence,Cardiac%20Dysfunction<\/a>\n <\/li>\n
  2. Please see the full Prescribing Information at www.ryoncil.com<\/a><\/li>\n<\/ol>\n

    \n Forward-Looking Statements<\/strong>
    \n
    This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast\u2019s preclinical and clinical studies, and Mesoblast\u2019s research and development programs; Mesoblast\u2019s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast\u2019s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast\u2019s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast\u2019s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast\u2019s ability to enter into and maintain established strategic collaborations; Mesoblast\u2019s ability to establish and maintain intellectual property on its product candidates and Mesoblast\u2019s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast\u2019s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast\u2019s financial performance; developments relating to Mesoblast\u2019s competitors and industry; and the pricing and reimbursement of Mesoblast\u2019s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast\u2019s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.<\/p>\n

    Release authorized by the Chief Executive.<\/p>\n

    \n For more information, please contact:<\/em>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n
    \n
    \n Corporate Communications \/ Investors<\/em>
    \n <\/strong>\n <\/td>\n    		\u00a0<\/td>\n<\/tr>\n
    Paul Hughes<\/td>\n\u00a0<\/td>\n<\/tr>\n
    T: +61 3 9639 6036<\/td>\n\u00a0<\/td>\n<\/tr>\n
    \u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
    \n
    \n Media \u2013 Global <\/em>
    \n <\/strong>\n <\/td>\n    		\n
    \n Media \u2013 Australia<\/em>
    \n <\/strong>\n <\/td>\n<\/tr>\n
    Rubenstein<\/td>\nBlueDot Media<\/td>\n<\/tr>\n
    Caroline Nelson<\/td>\nSteve Dabkowski<\/td>\n<\/tr>\n
    T: +1 703 489 3037<\/td>\nT: +61 419 880 486<\/td>\n<\/tr>\n
    E: cnelson@rubenstein.com<\/a><\/td>\nE: steve@bluedot.net.au<\/a><\/td>\n<\/tr>\n<\/table>\n

    \"\"
    \n
    \n \"\"\n <\/div>\n

    <\/div>\n","protected":false},"excerpt":{"rendered":"

    Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil\u00ae (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil\u00ae is the first mesenchymal stromal cell (MSC) product approved by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)2. This new registrational trial … <\/p>\n

    Continue reading “Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949703","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil\u00ae (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil\u00ae is the first mesenchymal stromal cell (MSC) product approved by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)2. This new registrational trial … Continue reading "Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T03:38:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy\",\"datePublished\":\"2026-04-08T03:38:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/\"},\"wordCount\":1346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/\",\"name\":\"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=\",\"datePublished\":\"2026-04-08T03:38:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/","og_locale":"en_US","og_type":"article","og_title":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk","og_description":"Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil\u00ae (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil\u00ae is the first mesenchymal stromal cell (MSC) product approved by FDA, and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)2. This new registrational trial … Continue reading \"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T03:38:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy","datePublished":"2026-04-08T03:38:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/"},"wordCount":1346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/","name":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=","datePublished":"2026-04-08T03:38:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTk0MSM3NTI0NzA3IzIwMTc0MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncil-in-duchenne-muscular-dystrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil\u00ae in Duchenne Muscular Dystrophy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949703"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949703\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}